Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CMChris MaharajALAna África Martín LópezABAna Benzaquén

Discussion

Loading...

Member takes

Overview

Multicenter study shows low CNS relapse rate of 1.6% in large B-cell lymphoma patients after CAR T-cell therapy, indicating effectiveness against progressive disease.

Key Points

  • CNS relapse incidence was 1.6% among CAR T-cell therapy patients with R/R large B-cell lymphoma, emphasizing a positive treatment outcome.
  • The study included 1102 R/R large B-cell lymphoma patients, with 875 in the CAR-T cohort and a median follow-up of 41 months.
  • Analysis revealed a low CNS relapse rate, presenting evidence that CAR T-cell therapy may reduce the risk of central nervous system complications.
  • Findings suggest that CNS prophylaxis may not be necessary for patients receiving CAR T-cell therapy in second-line treatment for large B-cell lymphoma.

Cite This Study

Maharaj et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e257https://doi.org/10.1182/blood-2025-5497
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile2025 · 1 citations
  2. 2Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement2025
  3. 3CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry2025
  4. 4Tandem combination of <scp>ASCT</scp> and <scp>CAR</scp> T‐cell therapy in highly refractory <scp>CNS</scp> lymphomas2025
  5. 5P14.07.B CAR T-CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS: A MULTICENTER RETROSPECTIVE STUDY FROM THE LOC NETWORK2025